- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04889443
Spontaneous Healing of ARticular Cartilage (SHARC) (SHARC)
How do Cartilage Injuries Heal Naturally? An Observational Study of Spontaneously Healing Cartilage Defects
Study Overview
Status
Conditions
Detailed Description
Osteoarthritis (OA) is a very common disease of the joints, for which in the United Kingdom alone almost 9 million people have sought treatment. This painful disease affects the cartilage and bone inside the joint. Many factors are known to increase the risk of getting osteoarthritis, or the rate at which it gets worse. Very important among these factors is an injury or a defect of the cartilage. It was believed for hundreds of years that cartilage, once injured, does not heal.
Research from the past 10 years is now throwing doubt on this old certainty, as researchers who took regular scans of volunteers over time noted that sometimes these defects come and then go. A Japanese group of surgeons decided to look again after a year to see what had happened to these defects, and noted that about half of them had got better! Cartilage defects in human therefore can heal, but nobody knows how this works.
For many years, our Center has helped patients who have knee cartilage damage by using the patients' own cartilage cells to help repair areas of damaged cartilage. This cell therapy starts by taking a piece of cartilage (10 mm) from the patient's knee, and this created defect always heals after a year. Thus, our proposal is to use our cell therapy patients as a human experimental model of natural cartilage healing using a wide range of techniques including Magnetic Resonance Imaging (MRI), visual inspection of the joint itself during knee joint surgery, examining biopsies of repair tissue down the microscope and measuring various kinds of molecules researchers think are important. The information gathered from these tests will help bridge the gap in our understanding of the mechanisms involved in the cartilage tissue regeneration.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
Shropshire
-
Oswestry, Shropshire, United Kingdom, SY10 7AG
- RJAH Orthopaedic Hospital NHS Foundation Trust
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Being able to provide signed and dated informed consent form.
Scheduled for one of the following surgical treatments
- Surgery that involves the harvest of cartilage tissue as part of the treatment, thus creating a fresh cartilage defect, which is then left to heal naturally. Examples of such surgery are autologous chondrocyte implantation (ACI) and mosaicplasty.
- Autologous stromal cell implantation (ASCI), as part of the ASCOT randomised clinical trial.
Exclusion Criteria:
- Inadequate understanding of verbal explanations or written information given in English, or having special communication needs.
- Chronic severe renal insufficiency
- Anything that would preclude the individual's full compliance with or completion of the study.
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Fraction of hyaline cartilage in harvest repair tissue
Time Frame: 1 year after tissue harvest
|
Fraction of hyaline or mixed hyaline/fibrous cartilage in a 1-year biopsy assessed using OsScore cartilage histology criteria
|
1 year after tissue harvest
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Visual quality of the repair tissue in harvest repair tissue
Time Frame: 1 year after tissue harvest
|
Visual quality of the repair tissue in a tissue biopsy obtained at 1 year, assessed using the corresponding item in the International Cartilage Repair Society (ICRS)-II arthroscopy score.
|
1 year after tissue harvest
|
|
Quality of harvest repair tissue assessed from MRI images
Time Frame: 1 year after tissue harvest
|
The quality of the repair tissue assessed from MRI images using the Magnetic Resonance Observation of Cartilage Repair Tissue (MOCART) score obtained at 1 year.
|
1 year after tissue harvest
|
|
Mean signal intensity of harvest repair tissue on MRI
Time Frame: 1 year after tissue harvest
|
The mean signal intensity of the repair tissue on an MRI T2 map obtained at 1 year
|
1 year after tissue harvest
|
|
Quality of harvest repair tissue assessed from a biopsy using the ICRS-II histology score
Time Frame: 1 year after tissue harvest
|
Quality of repair tissue assessed from a tissue biopsy at 1 year by the total ICRS-II histology score (ordinal scale from 0 to 140).
|
1 year after tissue harvest
|
|
Quality of harvest repair tissue assessed from a biopsy using the OsScore histology score
Time Frame: 1 year after tissue harvest
|
Quality of repair tissue assessed from a tissue biopsy at 1 year by the OsScore histology score (ordinal scale from 0 to 10).
|
1 year after tissue harvest
|
|
Correlation of harvest repair tissue quality with baseline risk of osteoarthritis
Time Frame: 1 year after tissue harvest
|
Correlation of total ICRS-II histology score of a repair tissue biopsy versus the baseline risk of osteoarthritis assessed using the minimal Rotterdam prediction model.
|
1 year after tissue harvest
|
|
Correlation of harvest repair tissue quality with local mechanical load at the defect
Time Frame: 1 year after tissue harvest
|
Correlation of quality of repair tissue (outcome 3) versus local mechanical load at the defect as assessed using gait analysis at baseline and 1 year.
|
1 year after tissue harvest
|
|
Match of biomarker level time course to a postulated pattern of cartilage repair, namely Inflammation-Repair-Remodelling.
Time Frame: 1 year after tissue harvest
|
Match of the time course of biomarker levels measured at baseline, 3 month and 1 year to a postulated pattern of cartilage repair, namely Inflammation-Repair-Remodelling.
|
1 year after tissue harvest
|
|
Correlation between levels of inflammatory biomarkers and inflammatory activity measured on dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) at baseline and 1 year.
Time Frame: 1 year after tissue harvest
|
Correlation between levels of inflammatory biomarkers and inflammatory activity measured on dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) at baseline and 1 year.
DCE-MRI is a non-invasive imaging technique used to determine the state of inflammation in tissue and is routinely used to assess inflammation in patients with rheumatoid arthritis.
The level of inflammation will be assessed as the percentage increase in signal intensity per second from the onset of signal increase until the maximum signal.
|
1 year after tissue harvest
|
|
Correlation of level of levels of inflammatory activity determined in a repair tissue biopsy versus that measured on DCE-MRI.
Time Frame: 1 year after tissue harvest
|
Correlation between grade of inflammatory biomarkers in a repair tissue biopsy at 1 year as analysed using immunohistochemistry (IHC) and level of inflammatory activity as measured on DCE-MRI.
The grade of inflammation on IHC will be assessed as the mean staining intensity per cell, and the level of inflammatory activity on DCE-MRI will be assessed as described for Outcome 10, but using a region of interest encompassing only the location of the biopsy.
|
1 year after tissue harvest
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Jan Herman Kuiper, PhD, Keele University
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- RG-0238-17-ISTM
- 18/NW/0291 (Other Identifier: REC North west - Liverpool East)
- 243678 (Other Identifier: Health Research Authority (HRA) UK)
- MR/N02706X/1 (Other Grant/Funding Number: MRC UK)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
The access will adhere to Keele University's Research Data Management Policy. Briefly, a data-sharing agreement must be issued and signed by appropriate authorities before data are released or analyses are performed on behalf of the requester.
The Data-sharing agreement will prohibit any attempt to (a) identify study participants from the released data or otherwise breach confidentiality, (b) make unapproved contact with study participants.
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.